1999
Structure of a Synthetic Glucose Derived Advanced Glycation End Product That Is Immunologically Cross-Reactive with Its Naturally Occurring Counterparts †
Al-Abed Y, Bucala R. Structure of a Synthetic Glucose Derived Advanced Glycation End Product That Is Immunologically Cross-Reactive with Its Naturally Occurring Counterparts †. Bioconjugate Chemistry 1999, 11: 39-45. PMID: 10639083, DOI: 10.1021/bc990061q.Peer-Reviewed Original ResearchConceptsAdvanced glycation end productsAnti-AGE antibodyGlycation end productsLow-density lipoproteinAGE-modified formCertain diabetic complicationsClasses of antibodiesBeta-amyloid peptideDiabetic complicationsPathological sequelaePrognostic informationAGE formationAGE adductsImmunoreactive fractionEnd productsInhibition of formationVivo ageAgeAntibodiesLines of evidenceVivoCross-linking adductsGlucoseTissueComplications
1985
Non‐enzymatic modification of proteins by steroids: Pathological implications for autoimmunity and glucocorticoid toxicity
Bucala R, Cerami A. Non‐enzymatic modification of proteins by steroids: Pathological implications for autoimmunity and glucocorticoid toxicity. BioEssays 1985, 3: 55-59. PMID: 3842583, DOI: 10.1002/bies.950030204.Peer-Reviewed Original ResearchConceptsOral contraceptive agentsElevated plasma levelsHigh steroid levelsGlucocorticoid toxicityPlasma levelsCovalent addition productsPathological sequelaeContraceptive agentsSteroid levelsCertain steroidsAddition productsSteroidsPathological implicationsRearrangement productsMicrosomal oxidationNon-enzymatic modification